It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Infiltrating gliomas are devastating and incurable tumors. Amongst all gliomas, those harboring a mutation in isocitrate dehydrogenase 1 mutation (IDH1mut) acquire a different tumor biology and clinical manifestation from those that are IDH1WT. Understanding the unique metabolic profile reprogrammed by IDH1 mutation has the potential to identify new molecular targets for glioma therapy. Herein, we uncover increased monounsaturated fatty acids (MUFA) and their phospholipids in endoplasmic reticulum (ER), generated by IDH1 mutation, that are responsible for Golgi and ER dilation. We demonstrate a direct link between the IDH1 mutation and this organelle morphology via D-2HG-induced stearyl-CoA desaturase (SCD) overexpression, the rate-limiting enzyme in MUFA biosynthesis. Inhibition of IDH1 mutation or SCD silencing restores ER and Golgi morphology, while D-2HG and oleic acid induces morphological defects in these organelles. Moreover, addition of oleic acid, which tilts the balance towards elevated levels of MUFA, produces IDH1mut-specific cellular apoptosis. Collectively, these results suggest that IDH1mut-induced SCD overexpression can rearrange the distribution of lipids in the organelles of glioma cells, providing new insight into the link between lipid metabolism and organelle morphology in these cells, with potential and unique therapeutic implications.
The understanding of altered lipid metabolism by isocitrate dehydrogenase 1 (IDH1) mutations in gliomas at a compartment-specific level is limited. Here, the authors use Raman spectroscopy to monitor organelle-specific metabolic changes and report that IDH1 mutations induce phospholipid imbalances which lead to ER and Golgi dilation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 University at Buffalo, State University of New York, Institute for Lasers, Photonics and Biophotonics, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887)
3 University at Buffalo, State University of New York, Institute for Lasers, Photonics and Biophotonics, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887); Advanced Cytometry Instrumentation Systems, LLC, Buffalo, USA (GRID:grid.273335.3)
4 Electron Microscopy Laboratory, Frederick National Laboratory for Cancer Research, Center for Cancer Research, National Cancer Institute, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
5 Electron Microscopy Laboratory, Frederick National Laboratory for Cancer Research, Center for Cancer Research, National Cancer Institute, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394); Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, Frederick, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
6 Undiagnosed Diseases Program, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, USA (GRID:grid.280128.1) (ISNI:0000 0001 2233 9230)
7 Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
8 Protein Characterization Laboratory of the Cancer Research Technology Program (CRTP), National Cancer Institute, Frederick, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
9 University Hospital Heidelberg, Division of Neurosurgical Research, Department of Neurosurgery, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)